针对多发性骨髓瘤的双特异性T细胞诱导疗法
Diana Cirstea1, Benjamin Puliafito1, Bridget E Kim2
1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Best practice & research. Clinical haematology
|September 7, 2025
概括
对多发性骨髓瘤 (MM) 患者来说,T细胞吸引疗法提供了新的希望,在复发或耐药病例中显示出高响应率. 早期使用和组合策略可能会改善长期结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 目前的多发性骨髓瘤 (MM) 治疗,包括三倍/四倍疗法和自身干细胞移植 (ASCT),实现了深度反应,但复发很常见.
- 第一次复发时的耐药性在MM管理中构成了重大治疗挑战.
- T细胞吸引剂 (TCE) 疗法已成为大量预先治疗的MM患者的有希望的免疫疗法选择.
研究的目的:
- 审查多发性骨髓瘤 (MM) 中T细胞吸引剂 (TCE) 疗法的设计和临床应用.
- 讨论TCE如何解决复发性或耐火性MM的治疗缺口.
- 探索组合方法和早期TCE利用的潜力,以提高治疗结果.
主要方法:
- 对多发性骨髓瘤T细胞参与治疗的临床数据和文献的审查.
- 美国食品和药物管理局批准的双特异性TCE (teclistamab,elranatamab,talquetamab) 的分析.
- 讨论治疗策略,包括组合疗法和门诊逐步增加剂量 (SUD).
主要成果:
- 在重度预治疗的MM患者中,TCE疗法显示出显著的响应率和长期缓解.
- 三种两种特异性TCE (teclistamab,elranatamab,talquetamab) 已经获得FDA的批准.
- 组合策略和早期启动TCE显示出克服阻力和改善响应深度/持久性的潜力.
结论:
- T细胞诱导疗法在治疗复发性/耐药性多发性骨髓瘤方面取得了重大进展.
- 通过组合和早期管理优化TCE的使用可能会改善患者的治疗结果.
- 门诊逐步增加剂量 (SUD) 有助于在社区环境中更广泛地采用TCE.
更多相关视频
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.6K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.7K
相关概念视频
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:17The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K